Pancreatic Cancer Research

ResearcherCatholic University of KoreaActive in the last 2 years

Myung Ah Lee

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1204-0574; OpenAlex author ID A5023344582, A5157887363, A5159651216. Sources: ClinicalTrials.gov.

Their work

Papers
22 (first author 0, last author 7)
Trials
1
Grants
0
Labs led
1
Collaborators
65
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 2 papers · 2019: 3 papers · 2020: 2 papers · 2021: 3 papers · 2022: 1 paper · 2023: 2 papers, 1 trial · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 22

  1. Efficacy of neoadjuvant FOLFIRINOX in resectable pancreatic cancer (NeoFOL-R): study protocol for an international, multicenter, prospective, randomized contro… Co-author DOI 10.1186/s12885-026-15639-6↗
  2. Pretreatment Serum GDF-15 and Features of Clinical Vulnerability in Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/jcm15207789↗
  3. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer. Co-author DOI 10.1016/j.esmoop.2025.105826↗
  4. Clinical and Molecular Characteristics of KRAS Codon-Specific Mutations in Advanced Pancreatic Ductal Adenocarcinoma with Prognostic and Therapeutic Implicatio… Co-author DOI 10.3390/ijms262210908↗
  5. The Role of Pretreatment Serum Interleukin 6 in Predicting Short-Term Mortality in Patients with Advanced Pancreatic Cancer. Last author DOI 10.3390/biomedicines12040903↗
  6. Clinical significance of serum-derived exosomal PD-L1 expression in patients with advanced pancreatic cancer. Co-author DOI 10.1186/s12885-023-10811-8↗
  7. Clinicopathological Features and Prognosis of Resected Pancreatic Ductal Adenocarcinoma Patients with Claudin-18 Overexpression. Co-author DOI 10.3390/jcm12165394↗
  8. Prognostic Implications of Portal Venous Circulating Tumor Cells in Resectable Pancreatic Cancer. Co-author DOI 10.3390/biomedicines10061289↗
  9. Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observat… Last author DOI 10.1186/s12885-020-07753-w↗
  10. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a r… Last author DOI 10.1186/s12885-021-08887-1↗
  11. Neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 as prognostic markers for advanced pancreatic cancer patients receiving first-line chemotherapy. Last author DOI 10.4251/wjgo.v13.i8.915↗
  12. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing… Co-author DOI 10.1186/s12885-020-07110-x↗
  13. Benefits of the multiplanar and volumetric analyses of pancreatic cancer using computed tomography. Co-author DOI 10.1371/journal.pone.0240318↗
  14. Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2019.1588↗
  15. β-Catenin expression is associated with cell invasiveness in pancreatic cancer. Last author DOI 10.3904/kjim.2017.155↗
  16. Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. Co-author DOI 10.4251/wjgo.v11.i11.1021↗
  17. Preoperative sarcopenia and post-operative accelerated muscle loss negatively impact survival after resection of pancreatic cancer. Co-author DOI 10.1002/jcsm.12274↗
  18. Evaluation of the prognostic value of the new AJCC 8th edition staging system for patients with pancreatic adenocarcinoma; a need to subclassify stage III? Co-author DOI 10.1016/j.ejca.2018.08.027↗
  19. Definitive concurrent chemoradiotherapy in locally advanced pancreatic cancer. Co-author DOI 10.3857/roj.2014.32.2.49↗
  20. Prognostic significance of autophagy-related protein expression in resected pancreatic ductal adenocarcinoma. Last author DOI 10.1097/mpa.0b013e318279d0dc↗
  21. Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with erlotinib (GE) in unresectable pancreatic cancer. Last author DOI 10.1007/s00432-012-1234-y↗
  22. The technical feasibility of an image-guided intensity-modulated radiotherapy (IG-IMRT) to perform a hypofractionated schedule in terms of toxicity and local c… Co-author DOI 10.1186/1748-717x-7-203↗

Trials 1

  1. Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients Study chair NCT06389552↗

Closest collaborators

The 25 strongest of 65 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tae Ho Hong · 15 shared papers, 2012–2026 · strength 2.42
  2. Kabsoo Shin · 8 shared papers, 2019–2026 · strength 1.68
  3. Se Jun Park · 8 shared papers, 2019–2026 · strength 1.68
  4. In-Ho Kim · 5 shared papers, 2021–2025 · strength 0.99
  5. In Seok Lee · 6 shared papers, 2012–2022 · strength 0.66
  6. Moon Hyung Choi · 5 shared papers, 2018–2022 · strength 0.63
  7. Seung Bae Yoon · 4 shared papers, 2018–2022 · strength 0.46
  8. Eun Sun Jung · 3 shared papers, 2018–2022 · strength 0.37
  9. Ja Hee Suh · 2 shared papers, 2021–2023 · strength 0.36
  10. Hei‐Cheul Jeung · 2 shared papers, 2025–2026 · strength 0.36
  11. Ji Hyun Lee · 1 shared paper, 2026 · strength 0.33
  12. Meiying Song · 3 shared papers, 2018–2020 · strength 0.29
  13. Do‐Youn Oh · 2 shared papers, 2019–2026 · strength 0.27
  14. Dongwoo Cho · 1 shared paper, 2025 · strength 0.26
  15. Ho Joong Choi · 2 shared papers, 2018–2022 · strength 0.25
  16. Julian Choi · 1 shared paper, 2026 · strength 0.19
  17. Jin-Young Jang · 1 shared paper, 2026 · strength 0.19
  18. Ju Won Kim · 1 shared paper, 2026 · strength 0.19
  19. Hye Jin Choi · 1 shared paper, 2026 · strength 0.19
  20. In Woong Han · 1 shared paper, 2026 · strength 0.19
  21. Yoo‐Seok Yoon · 1 shared paper, 2026 · strength 0.19
  22. Keun Soo Ahn · 1 shared paper, 2026 · strength 0.19
  23. Hye‐Sol Jung · 1 shared paper, 2026 · strength 0.19
  24. Chang-Sup Lim · 1 shared paper, 2026 · strength 0.19
  25. Hyung Il Seo · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.